Please wait
0001650648EX-FILING FEESfalsefalsefalseCommon stock, $0.0001 par value per shareCommon stock, $0.0001 par value per shareCommon stock, $0.0001 par value per share 0001650648 2025-02-28 2025-02-28 0001650648 1 2025-02-28 2025-02-28 0001650648 2 2025-02-28 2025-02-28 0001650648 3 2025-02-28 2025-02-28 iso4217:USD xbrli:pure xbrli:shares
Exhibit 107.1
Calculation of Filing Fee Tables
Form
S-8
(Form Type)
4D Molecular Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1—Newly Registered Securities
 
               
Security Type 
 
Security
Class
Title
 
Fee
Calculation
Rule
 
Amount
to be
Registered(1)
 
Proposed
Maximum
Offering
Price Per
Unit
 
Maximum
Aggregate
Offering
Price
 
Fee
Rate
 
Amount of
Registration
Fee
               
Equity  
Common stock,
$0.0001 par value per share
  Rule 457(c) and Rule 457(h)   2,289,625
(2)
  $4.67
(5)
  $10,692,548.75   $0.0001531   $1,637.03
               
Equity  
Common stock,
$0.0001 par value per share
  Rule 457(c) and Rule 457(h)   150,000
(3)
  $3.97
(6)
  $595,500.00   $0.0001531   $91.18
               
Equity  
Common stock,
$0.0001 par value per share 
  Rule 457(c) and Rule 457(h)    500,000
(4)
  $4.67
(5)
  $2,335,000.00   $0.0001531   $357.49
         
Total Offering Amounts
    $13,623,048.75     $2,085.70
         
Total Fee Offsets
(7)
        $
         
Net Fee Due
              $2,085.70
 
(1)
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall also cover any additional shares of 4D Molecular Therapeutics, Inc.’s (the “Registrant”) common stock that become issuable under the 2020 Incentive Award Plan (the “2020 Plan”), the 2020 Employee Stock Purchase Plan (the “ESPP”) and the 2025 Employment Inducement Award Plan (the “Inducement Plan”) by reason of any stock dividend, stock split, recapitalization or similar transaction effected without the Registrant’s receipt of consideration which would increase the number of outstanding shares of common stock.
(2)
Represents the additional shares of common stock available for future issuance under the Registrant’s 2020 Plan resulting from an annual increase as of January 1, 2025.
(3)
Represents the additional shares of common stock available for future issuance under the Registrant’s ESPP resulting from an annual increase as of January 1, 2025.
(4)
Represents the additional shares of common stock available for future issuance under the Registrant’s Inducement Plan resulting from its adoption as of February 3, 2025.
(5)
Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) and Rule 457(c) of the Securities Act. The proposed maximum offering price per share and the proposed maximum aggregate offering price for shares reserved for future issuance under the 2020 Plan, the ESPP and the Inducement Plan are based on the average of the high and the low price of Registrant’s Common Stock as reported on the Nasdaq Global Select Market on February 24, 2025, which was $4.67.
(6)
Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) and Rule 457(c) of the Securities Act on the basis of the average of the high and the low prices of common stock as reported on the Nasdaq Global Select Market on February 24, 2025, multiplied by 85%. Pursuant to the ESPP, the purchase price of the shares of common stock reserved for issuance thereunder will be at least 85% of the lower of the fair market value of a share of common stock on the applicable Grant Date or applicable Exercise Date.
(7)
The Registrant does not have any fee offsets.